Scientific deep-dive

GLP-1s and Daytime Sleepiness

A cohort found more diagnoses of excessive daytime sleepiness, at a 21% relative increase, which is 0.4% in absolute terms at one year. Four other sleep outcomes showed nothing.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

A real-world cohort found GLP-1 users more likely to be diagnosed with hypersomnolence (excessive daytime sleepiness), with hazard ratios of 1.21 at one year and 1.23 at five. Before that sounds alarming, look at the absolute figures: roughly a 0.4% increase at one year and 0.7% at five.[1]

What was and was not found

The signal was specific rather than general, which is the most informative part of the study.

Sleep and related outcomes in a real-world cohort of GLP-1 users.[1]
OutcomeFinding
HypersomnolenceIncreased, HR 1.21 at 1 year and 1.23 at 5 (absolute +0.4% at 1 year, +0.7% at 5)
Iron deficiencyIncreased at 5 years, HR 1.11 (95% CI 1.06–1.16)
ParasomniaNo significant association
Disturbed sleepNo significant association
Restless legs syndromeNo significant association
Narcolepsy / cataplexyNo significant association

One sleep outcome moved and four did not. That is a narrower and more credible finding than “these drugs affect sleep”, because a broad disruption of sleep architecture would be expected to show up in more than one place. Dreams were not among the outcomes; what is known about those is in GLP-1s, vivid dreams and nightmares.

Why the absolute numbers matter here more than usual

A 21% relative increase on a rare diagnosis is four extra people per thousand.

Daytime sleepiness is also one of the most confounded symptoms it is possible to study in this population. Obesity causes it. Sleep apnea causes it, and is very common in the same people (our sleep apnea article covers a trial in exactly that group). Depression causes it. Eating far less causes it. Any of those could produce a diagnosis code without the drug doing anything.

There is also a detection effect: people starting a new medication see clinicians more often, and symptoms that were always present get recorded for the first time.

The iron finding is the practical one

Iron deficiency rose at five years, at a hazard ratio of 1.11 with a tight confidence interval.[1] That is a small effect and a mechanistically obvious one: eating substantially less, for years, reduces intake of everything, and iron is among the first things to run short.

It is also directly actionable, which the sleepiness finding is not. Iron studies are one of the tests in the monitoring panel we covered in protein targets and the lab panel, and this is the sort of evidence that panel exists for. Iron deficiency also causes fatigue, so some of the sleepiness signal may simply be the iron finding wearing a different diagnosis code.

The Parkinsonism finding should not be reported as a benefit, and we are not reporting it as one. The study found a hazard ratio of 0.26 (a 74% reduction) and states that event counts were low. A dramatic ratio built on a handful of events is exactly the shape we take apart in when a hazard ratio is too good. The randomized trials in people who already have Parkinson’s are set out in GLP-1 drugs and Parkinson’s.

Frequently Asked Questions

A real-world cohort found more diagnoses of excessive daytime sleepiness, at hazard ratios of 1.21 at one year and 1.23 at five, but the absolute increase was around 0.4% at one year and 0.7% at five. Four other sleep outcomes showed no association at all.
Easily. Obesity, sleep apnea, depression and eating very little all cause daytime sleepiness, and all are common in this population. People starting a new drug also see clinicians more often, so long-standing symptoms get recorded for the first time.
Iron deficiency rose at five years with a hazard ratio of 1.11. That is small but mechanistically obvious, since eating much less for years reduces intake of everything. It is the actionable result here, and iron studies are already part of the recommended monitoring panel.
Plausibly. Iron deficiency causes fatigue, so part of the sleepiness signal may be the iron finding appearing under a different diagnosis. The study does not separate them.
No conclusion should be drawn. The study reported a hazard ratio of 0.26 while noting event counts were low, and a dramatic ratio built on very few events is the least reliable kind of finding.

References

  1. 1.Kamel-Abusalha L, Afifi AM, Dawoud A, et al. Association of GLP-1 Receptor Agonist Use with Hypersomnolence: A Real-world Cohort Analysis Journal of Diabetes and Metabolic Disorders. 2026. PMID: 41867417.

Ozempic Dreams and Nightmares: What the Evidence Shows

No study has measured dreams on Ozempic, Wegovy, Mounjaro or Zepbound, and none of the labels lists abnormal dreams or nightmares. What FDA reports, signal studies and sleep research do show, and when night-time low blood sugar is the real cause.

9 min read

Semaglutide and Alzheimer's: The Trials Came Back Negative

Two randomized trials in 3,808 people with early Alzheimer's found no difference in cognitive decline at two years. Both were discontinued for negative clinical outcome. The 45% figure came from studies measuring something else.

6 min read

BPC-157 vs TB-500: Two Recovery Peptides, One With No Human Studies

BPC-157 has three small uncontrolled human reports, and FDA found no human study of TB-500. Since October 28, 2026, an HHS policy covers compounded BPC-157 acetate by injection, capsule or topical product and TB-500 acetate by injection only. Blends are not covered.

9 min read

Retatrutide's Phase 3, and the Gray Market

A triple-receptor agonist cut HbA1c 1.94 points and weight 15.3% in a phase 3 trial. It is approved nowhere, and eight sellers in our register are already shipping something by that name.

8 min read

GLP-1s and Autoimmune Thyroiditis: An Association, and the Reason to Doubt It

A 290,770-pair cohort found autoimmune thyroiditis diagnosed 30% more often on a GLP‑1 than on a DPP-4 inhibitor. Everyone on a GLP‑1 gets a boxed thyroid warning and the comparison group does not, and this disease is found by testing.

6 min read

Zepbound for Sleep Apnea: What SURMOUNT-OSA Actually Found

On December 20, 2024 the FDA cleared Zepbound for obstructive sleep apnea, and no other drug of any kind holds that indication. The trials cut breathing interruptions by 25 to 29 an hour, and left the average participant still inside the moderate band.

7 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

9.1

Collective

Flat any-dose pricing, if you can absorb a $199 annual membership on top

From $59/mo + membership

Get started →
Read full review →
9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →